VIENNA — In a Healio video exclusive, Maria T. Abreu, MD, reported mirikizumab induced “rapid control” of bowel movement urgency and fatigue among patients with mild to moderate ulcerative colitis.
Specifically, compared with placebo, patients treated with mirikizumab had improved rectal bleeding (approx. 64% vs. 43%), stool frequency (60% vs. 40%) and bowel urgency (22% vs. 12%) as well as achieved symptomatic remission (45% vs. 30%) at 4 weeks.
“The final thing I’ll tell you is that there was an improvement in fatigue and abdominal pain,” Abreu, professor of